Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Nephrosis

3

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

Possibly Marketed Outside US

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

dopamine receptor D1

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

3

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Yamanouchi Pharmaceutical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

3

PUBCHEM

3

CAS

2

EPA CompTox

2

ChEMBL

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ZELANDOPAM

IR6XYD8SAX

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

dopamine receptor D1

Conditions:

Congestive heart failure

Acute renal failure

YM-435 is a dopamine D1 agonist. The renal and cardiovascular effects of YM-435 may be suitable for the treatment of patients with renal insufficiency, heart failure and hypertension. It has been in phase II clinical trials for the treatment of heart...

failure and hypertension. YM435 may be useful in the preservation of renal function in ischemia-induced acute renal failure. Also, it might be a useful as therapeutic agent for the treatment of congestive heart failure.

ZELANDOPAM HYDROCHLORIDE MONOHYDRATE

5Q871HX1RH

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

dopamine receptor D1

Conditions:

Congestive heart failure

Acute renal failure

YM-435 is a dopamine D1 agonist. The renal and cardiovascular effects of YM-435 may be suitable for the treatment of patients with renal insufficiency, heart failure and hypertension. It has been in phase II clinical trials for the treatment of heart...

failure and hypertension. YM435 may be useful in the preservation of renal function in ischemia-induced acute renal failure. Also, it might be a useful as therapeutic agent for the treatment of congestive heart failure.

ZELANDOPAM HYDROCHLORIDE

99I770UEI4

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

dopamine receptor D1

Conditions:

Congestive heart failure

Acute renal failure

YM-435 is a dopamine D1 agonist. The renal and cardiovascular effects of YM-435 may be suitable for the treatment of patients with renal insufficiency, heart failure and hypertension. It has been in phase II clinical trials for the treatment of heart...

failure and hypertension. YM435 may be useful in the preservation of renal function in ischemia-induced acute renal failure. Also, it might be a useful as therapeutic agent for the treatment of congestive heart failure.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1